Aim: To conduct a pilot open-label study of semaglutide in lung transplant candidates with obesity. - We will get an estimate of recruitment fraction and retention on study drug. - We will determine preliminary effect estimates of change in weight, percent body fat, skeletal muscle mass, and circulating levels of leptin, c-reactive protein, glycated hemoglobin, and free fatty acids. - We will evaluate medication tolerability and side effects over 12 weeks of therapy. - We will determine feasibility of a protocol for titrating semaglutide to a target weight. Medication tolerability and side effects over 12 weeks of therapy. The primary outcome will be the number of subjects who remain on therapy at 12 weeks. Change in weight, percent body fat, skeletal muscle mass, and circulating levels of leptin, c-reactive protein, glycated hemoglobin, and free fatty acids after 12 weeks of therapy. We will evaluate recruitment fraction and retention on study drug. We will determine feasibility of a protocol for titrating semaglutide to a target weight.

You may be eligible for this study if you meet the following criteria:

• Conditions: Medical Research
• Age: - 99 Years
• Gender: All